MNOV Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States...

Stats
Tagesvolumen	14 451.00
Durchschnittsvolumen	49 646.00
Marktkapitalisierung	63.27M
EPS	$0 ( 2024-02-15 )
Nächstes Ertragsdatum	( $-0.0500 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.59
ATR14	$0.0140 (1.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-09	Obrien Geoffrey	Buy	84 000	Employee Stock Option (Right to Buy)
2024-01-09	Matsuda Kazuko	Buy	157 500	Employee Stock Option (Right to Buy)
2024-01-09	Iwaki Yuichi	Buy	210 000	Employee Stock Option (Right to Buy)
2023-08-04	Lemerond Nicole	Buy	18 333	Stock Option (Right to Buy)
2023-08-04	Lemerond Nicole	Buy	0

INSIDER POWER
98.73
Last 93 transactions
Buy: 6 161 551 \| Sell: 1 269 768

MediciNova Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

MediciNova Inc Finanzdaten

Annual	2023
Umsatz:	$1.00M
Bruttogewinn:	$979 705 (97.97 %)
EPS:	$-0.170

FY	2023
Umsatz:	$1.00M
Bruttogewinn:	$979 705 (97.97 %)
EPS:	$-0.170

FY	2022
Umsatz:	$0
Bruttogewinn:	$-212 426 (0.00 %)
EPS:	$-0.290

FY	2021
Umsatz:	$4.04M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.207

Financial Reports:

No articles found.

MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.